ABBV-744 + ruxolitinib

ABBV-744 + ruxolitinib is an investigational **combination therapy** composed of ABBV-744, a highly selective small molecule **inhibitor** of the BD2 domain of the BET protein family (bromodomain and extra-terminal domain family: BRD2, BRD3, BRD4), and ruxolitinib, a small molecule **Janus kinase (JAK) 1/2 inhibitor**[1][2][3][4][5][6]. ABBV-744 was developed by AbbVie and is intended to address the unmet needs in myelofibrosis and possibly other myeloproliferative neoplasms by targeting the epigenetic regulation of disease pathogenesis, potentially reducing fibrosis and modifying disease biology, while ruxolitinib targets abnormal JAK-STAT signaling central to the disease. The combination is under clinical investigation (Phase 1b) for safety, tolerability, and early efficacy, particularly in patients with myelofibrosis who are JAK inhibitor–refractory, resistant, or JAK inhibitor–naïve[1][5].